PeptiDream

Kleo Pharmaceuticals, Inc. is a biotechnology company based in New Haven, Connecticut, focused on developing immunotherapies that harness the body's immune system to combat cancer and infectious diseases. Founded in 2015, the company specializes in two innovative classes of small molecules: Antibody Recruiting Molecules (ARMs) and Synthetic Antibody Mimics (SyAMs). These compounds are designed to be non-immunogenic, highly stable, and lower in molecular weight, which allows for faster and more cost-effective production compared to traditional biologics. Kleo's technology aims to provide safer and more effective treatment options, enabling healthcare professionals to initiate cancer therapies promptly, thus increasing the chances of successful outcomes. As of January 2021, Kleo operates as a subsidiary of Biohaven Pharmaceutical Holding Company Ltd.

Modulus Co., Ltd., established in 2016 and based in Tokyo, Japan, specializes in drug discovery with a focus on developing small-molecule therapeutics for oncology, chronic inflammation, immune disorders, and rare genetic conditions. The company employs advanced computational techniques, including virtual screening and machine learning algorithms, to facilitate the rapid design and generation of drug candidates targeting high-value diseases. Modulus Discovery's innovative platform integrates biological insights with computational drug discovery expertise, allowing for dynamic simulations of proteins in solvated environments. The firm also has an office in Cambridge, Massachusetts, and boasts a team of experts in drug design and disease biology, many of whom have extensive research and development experience in leading pharmaceutical and biotechnology firms.

PeptiStar Inc., founded in 2017 and headquartered in Osaka, Japan, specializes in the development and manufacturing of peptide medicines. As a Contract Development and Manufacturing Organization (CDMO), PeptiStar offers a range of services for peptide active pharmaceutical ingredients (APIs), including traditional and advanced forms such as macrocyclic and stapled peptides that incorporate non-natural amino acids. The company focuses on innovative manufacturing technologies to enhance the efficiency and effectiveness of peptide therapeutics, thereby supporting the pharmaceutical industry in accelerating drug development. Through its commitment to open innovation, PeptiStar aims to deliver high value-added services to its clients, contributing significantly to advancements in peptide medicine.